This topic will review therapies for patients with HFrEF who have mild to moderate symptoms of HF despite initial pharmacologic therapy with a renin
Crossref Medline Google Scholar; 167
ALDACTONE® (spironolactone) Indications and Usage 1 INDICATIONS AND USAGE 1
Using multivariate regression, we found many factors affecting spironolactone utilization, including EF before spironolactone, serum creatinine
We analyzed hazard ratios (HRs) for
Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase
This meta-analysis investigated the This was then instituted for patients with signs and symptoms of progression of heart failure despite receiving 25 mg/d spironolactone
Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure
J Am Coll Cardiol
Management of chronic heart failure (Guideline 147)
Spironolactone for heart failure with preserved ejection fraction
ACC/AHA Joint Committee Members
2006;73 (7):1263-1266
Initially 1–2 mg/kg daily in 1–2 divided doses; increased if necessary up to 7 mg/kg daily, in resistant ascites